CT-071

N/A

Report date: 2024/03/28 20:00:34

Base Information

Drug NameCT-071
Drug Alias NameGPRC5D targeted CAR T cell therapy(CARsgen Therapeutics)CT071CT-071
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionAnti-GPRC5DImmunologic cytotoxicityT lymphocyte replacements
TargetsG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCARsgen Therapeutics Holdings LtdCarsgen Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A